<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016924</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-216-0128</org_study_id>
    <secondary_id>2013-001402-28</secondary_id>
    <nct_id>NCT02016924</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety, and Efficacy of Cobicistat-boosted Atazanavir or Cobicistat-boosted Darunavir in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects</brief_title>
  <official_title>A Phase 2/3, Multicenter, Open-label, Multicohort, Two-Part Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co), Administered With Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the steady-state pharmacokinetics (PK)
      and confirm the dose of cobicistat-boosted atazanavir (ATV/co) or cobicistat-boosted
      darunavir (DRV/co) in HIV-1 infected antiretroviral treatment-experienced, virologically
      suppressed, pediatric participants between the ages of 3 months to &lt; 18 years of age.

      This study will also evaluate the safety, tolerability, and efficacy of ATV/co or DRV/co each
      co-administered with a background regimen (BR) through 48 weeks and during the 5 year
      long-term treatment.

      There will be 2 parts to the study.

        -  Part A: Participants will be enrolled sequentially by age cohort to evaluate the steady
           state PK and confirm dose of ATV/co and DRV/co. Following screening, enrolled
           participants will continue their suppressive regimen of either ATV/r or DRV/r once-daily
           plus their BR. On Day 1, participants will discontinue ritonavir and initiate once daily
           cobicistat (COBI) to be taken with their ATV or DRV plus their BR. All participants
           enrolled in Part A will participate in an intensive PK evaluation of COBI and ATV or DRV
           on Day 10. Following completion of the intensive PK visit, participants will continue to
           receive COBI coadministered with DRV or ATV each with a BR and return for scheduled
           study visits.

        -  Part B: Participants will be enrolled to evaluate the safety, tolerability, and efficacy
           of the ATV/co or DRV/co regimen. For all cohorts in Part B, participants will be
           screened and initiated sequentially by each age cohort following confirmation of
           appropriate COBI exposure and PI exposures from the corresponding age cohort in Part A.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2014</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUCtau of ATV and DRV</measure>
    <time_frame>Predose and up to 12 hours postdose on Day 10</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events and Laboratory Abnormalities</measure>
    <time_frame>Up to 6 years plus 30 days</time_frame>
    <description>Incidence of adverse events and graded laboratory abnormalities will be summarized across the participant population. Graded laboratory abnormalities are those with at least one grade shift from baseline using the Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Ctau of ATV, DRV, and Cobicistat</measure>
    <time_frame>Predose and up to 12 hours postdose on Day 10</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax of ATV, DRV, and Cobicistat</measure>
    <time_frame>Predose and up to 12 hours postdose on Day 10</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: CL/F of ATV, DRV, and Cobicistat</measure>
    <time_frame>Predose and up to 12 hours postdose on Day 10</time_frame>
    <description>CL/F is defined as the apparent oral clearance following administration of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUCtau of Cobicistat</measure>
    <time_frame>Predose and up to 12 hours postdose on Day 10</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Vz/F of Cobicistat</measure>
    <time_frame>Predose and up to 12 hours postdose on Day 10</time_frame>
    <description>Vz/F is defined as the apparent volume of distribution of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Plasma HIV-1 RNA &lt; 50 Copies/mL at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Plasma HIV-1 RNA &lt; 50 Copies/mL at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Plasma HIV-1 RNA &lt; 50 Copies/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Plasma HIV-1 RNA &lt; 50 Copies/mL Every 12 Weeks After Week 48</measure>
    <time_frame>Every 12 weeks after Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pure Virologic Failure</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Pure virologic failure includes participants who have confirmed rebound (ie, HIV-1 RNA ≥ 50 copies/mL on 2 consecutive visits or the last available HIV-1 RNA ≥ 50 copies/mL during study followed by premature discontinuation of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in log10 HIV-1 RNA (Copies/mL) at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in log10 HIV-1 RNA (Copies/mL) at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in log10 HIV-1 RNA (Copies/mL) Every 12 Weeks After Week 48</measure>
    <time_frame>Every 12 weeks after Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4+ Cell Count (Cells/µL) at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4+ Cell Count (Cells/µL) at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4+ Cell Count (Cells/µL) Every 12 Weeks After Week 48</measure>
    <time_frame>Every 12 weeks after Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4 Percentage at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4 Percentage at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4 Percentage Every 12 Weeks After Week 48</measure>
    <time_frame>Every 12 weeks after Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability and Palatability of Cobicistat</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Acceptability and palatability of cobicistat tablets and/or dispersible tablets in each cohort will be summarized.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acquired Immune Deficiency Syndrome (AIDS)</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 12 to &lt;18 years old will receive cobicistat 150 mg with either ATV or DRV plus BR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 6 to &lt;12 years old will receive cobicistat 150 mg (150 mg if ≥ 25 kg) or cobicistat 90 mg (if ≥ 15 kg and &lt; 25 kg) with either ATV or DRV plus BR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 3 to &lt;6 years old will receive cobicistat (dose to be determined) with either ATV or DRV plus BR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 3 months to &lt;3 years old will receive cobicistat (dose to be determined) with ATV plus BR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 12 to &lt;18 years old will receive cobicistat 150 mg with either ATV or DRV plus BR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 6 to &lt;12 years old will receive cobicistat 150 mg (150 mg if ≥ 25 kg) or cobicistat 90 mg (if ≥ 15 kg and &lt; 25 kg) with either ATV or DRV plus BR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 3 to &lt;6 years old will receive cobicistat (dose to be determined) with either ATV or DRV plus BR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 3 months to &lt;3 years old will receive cobicistat (dose to be determined) with ATV plus BR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATV</intervention_name>
    <description>Capsules or powder administered once daily according to dosing recommendations per product monograph</description>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_label>Part A, Cohort 2</arm_group_label>
    <arm_group_label>Part A, Cohort 3</arm_group_label>
    <arm_group_label>Part A, Cohort 4</arm_group_label>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <arm_group_label>Part B, Cohort 2</arm_group_label>
    <arm_group_label>Part B, Cohort 3</arm_group_label>
    <arm_group_label>Part B, Cohort 4</arm_group_label>
    <other_name>Reyataz®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRV</intervention_name>
    <description>Tablets or liquid oral suspension administered once daily according to dosing recommendations per product monograph</description>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_label>Part A, Cohort 2</arm_group_label>
    <arm_group_label>Part A, Cohort 3</arm_group_label>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <arm_group_label>Part B, Cohort 2</arm_group_label>
    <arm_group_label>Part B, Cohort 3</arm_group_label>
    <other_name>Prezista®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobicistat</intervention_name>
    <description>Tablets or dispersible tablets as an oral suspension administered orally once daily with food</description>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_label>Part A, Cohort 2</arm_group_label>
    <arm_group_label>Part A, Cohort 3</arm_group_label>
    <arm_group_label>Part A, Cohort 4</arm_group_label>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <arm_group_label>Part B, Cohort 2</arm_group_label>
    <arm_group_label>Part B, Cohort 3</arm_group_label>
    <arm_group_label>Part B, Cohort 4</arm_group_label>
    <other_name>GS-9350</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR</intervention_name>
    <description>Background regimen (BR) must include 2 nucleoside reverse transcriptase inhibitors (NRTI). The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.</description>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_label>Part A, Cohort 2</arm_group_label>
    <arm_group_label>Part A, Cohort 3</arm_group_label>
    <arm_group_label>Part A, Cohort 4</arm_group_label>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <arm_group_label>Part B, Cohort 2</arm_group_label>
    <arm_group_label>Part B, Cohort 3</arm_group_label>
    <arm_group_label>Part B, Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  HIV-1 infected treatment-experienced, virologically suppressed males and females aged
             3 months to &lt; 18 years at the Day 1 visit (according to requirements of enrolling
             Cohort)

          -  Are able to provide written assent if they have the ability to read and write

          -  Parent or legal guardian able to provide written informed consent prior to any
             screening evaluations and willing to comply with study requirements

          -  Body weight at screening ≥ 25 kg (Cohorts 1 and 2), 15 kg to &lt; 25 kg (Cohort 2), or to
             be determined (Cohorts 3 and 4) dependent upon age cohort

          -  Adequate renal function

          -  Adequate hematologic function

          -  Adequate hepatic function defined as

               -  Hepatic transaminases (AST and ALT) ≤ 5 x upper limit of normal (ULN)

               -  Total bilirubin ≤ 1.5 mg/dL or a normal direct bilirubin

          -  Negative serum pregnancy test

          -  Individuals with evidence of suppressed viremia (&lt; 50 copies/mL) at study entry

          -  Stable antiretroviral regimen including 2 nucleoside reverse transcriptase inhibitors
             and either ritonavir-boosted atazanavir or ritonavir-boosted darunavir once or twice
             daily as per product label for a minimum of 3 months prior to the screening visit.
             Treatment-experienced pediatric individuals taking DRV/r must have no history of DRV
             resistance associated mutations.

          -  Males and females of childbearing potential must agree to utilize highly effective
             contraception methods while on study treatment or agree to abstain from heterosexual
             intercourse throughout the study period and for 30 days following the last dose of
             study drug

          -  Documented negative screening for active pulmonary tuberculosis (TB) per local
             standard of care within 6 months of a screening visit

          -  Must be willing and able to comply with all study requirements

          -  No opportunistic infection within 30 days of study entry (at Day -10)

        Key Exclusion Criteria:

          -  Individuals with CD4+ cell counts at screening of less than 200 cells/mm^3

          -  An AIDS defining condition with onset within 30 days prior to screening

          -  Life expectancy of less than 1 year

          -  An ongoing serious infection requiring systemic antibiotic therapy at the time of
             screening.

          -  Evidence of active pulmonary or extra-pulmonary tuberculosis disease:

               -  Within 3 months of the screening visit for all individuals 6 months of age or
                  older

               -  At anytime for individuals younger than 6 months

          -  Anticipated requirement for rifamycin treatment while participating in the study.
             Note: prophylactic isoniazid therapy for latent TB is allowed.

          -  Active hepatitis C virus (HCV) infection. Note: individuals with positive HCV antibody
             and without detectable HCV RNA are permitted to enroll.

          -  Positive Hepatitis B surface antigen or other evidence of active hepatitis B virus
             (HBV) infection. Note: individuals with positive HBV surface antibody and no evidence
             of active HBV infection are permitted to enroll.

          -  Individuals with clinically significant abnormal ECGs

          -  Have any serious or active medical or psychiatric illness which, in the opinion of the
             investigator, would interfere with treatment, assessment, or compliance with the
             protocol.

          -  Individuals experiencing decompensated cirrhosis

          -  A history of or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal
             cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma.

          -  Pregnant or lactating females.

          -  Current alcohol or substance abuse judged by the investigator to potentially interfere
             with compliance.

          -  Have history of significant drug sensitivity or drug allergy.

          -  Known hypersensitivity to the study drug, the metabolites, or formulation excipients.

          -  Have previously participated in an investigational trial involving administration of
             any investigational agent within 30 days prior to the study dosing.

          -  Participation in any other clinical trial, including observational studies, without
             prior approval from sponsor is prohibited while participating in this trial.

          -  Individuals receiving ongoing therapy with any medication that is not to be taken with
             COBI or a component of the BR

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>GSUS2160128@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pediatric Infectious Diseases Associate</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jagmohan Batra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elizabeth McFarland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Natella Rakhmanina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida Clinic at Children's Medical Services</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carina Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rana Chakraborty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Borkowsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leonard Weiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aditya Gaur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gloria Heresi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. Cosme Argerich</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1151</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Diego Cecchini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Salud S.A.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1131ACG</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria R Bologna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramos Mejía</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1221ADC DF</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Irene Foradori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Huesped</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pedro Cahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kulkanya Chokephaibulkit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The HIV NAT Research Collaboration</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sivaporn Getechompol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pope Kosalaraksa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatrics</keyword>
  <keyword>Adolescents</keyword>
  <keyword>HIV</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

